J&J: Carvykti Delivers Five-Year Treatment-Free Remissions In 50% Of Early Line RRMM Patients

Single Infusion Of Carvykti Delivered Five-Year Treatment-Free Remissions In 50% Of Patients In Early Line Relapsed/Refractory Multiple Myeloma